Closes $16.6 Million Offering - Ladenburg Thalmann

Drug Pipeline Expanding - Zachs Says - Consensus  Buy

Wall Street Research Report

Jaguar Health is expanding its pipeline day by day. This company has made enormous strides in developing its product line of drugs and health care products.  With $16 million in new cash on hand further build out is assured  Wall Street Daily

These shares have been consolidating building a solid base .
Over the past two weeks shares of JAGX have rallied from levels around $1.05 to current levels around $1.50. After testing resistance at the $1.45 level for a few days it broke through to the upside. ( SEE TECHNICAL ANALYSIS

Buffetts Billions - 2019 He Made $18 Billion In 3 Stocks 
-  NYSE Canopy Growth  - Analyst Says BUY 

Serious investors should immediately place these shares on their BUY LIST . Three analysts rate this stock a buy with one rating JAGX A STRONG BUY  -  



HC Wainwright set a $10.00 price target on shares of Jaguar Health and gave the stock a “buy” rating in a research report on Tuesday, July 2nd.

Zacks: Jaguar Health Inc (NASDAQ:JAGX) Given Consensus Recommendation of "Buy" by Analysts

Shares of Jaguar Health Inc (NASDAQ:JAGX) have been assigned an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company. Jaguar Health’s rating score has declined by 100% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokers have set a one year consensus price objective of $10.00 for the company and are anticipating that the company will post ($5.61) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Jaguar Health an industry rank of 77 out of 256 based on the ratings given to related companies.

Several research firms recently commented on JAGX. . ValuEngine raised shares of Jaguar Health from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright set a $10.00 price target on shares of Jaguar Health and gave the stock a “buy” rating in a research report on Tuesday, July 2nd.

Jaguar Health (NASDAQ:JAGX) last posted its quarterly earnings data on Tuesday, May 21st. The biotechnology company reported ($12.59) EPS for the quarter, beating the consensus estimate of ($13.29) by $0.70. The business had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $2.20 million. Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 826.41%. Sell-side analysts forecast that Jaguar Health will post -6.07 earnings per share for the current year.

In other Jaguar Health news, Director James J. Bochnowski purchased 180,582 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were purchased at an average cost of $2.00 per share, with a total value of $361,164.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.81% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Zachs rates this stock a hold

Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer

Company's Legacy Animal Health Business Supports Focus on Human Health Benefits

SAN FRANCISCO, CA / ACCESSWIRE / September 18, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued the following updates today regarding the Company's September 11, 2019 pre-submission conference with the U.S. Food & Drug Administration's Center for Veterinary Medicine (CVM) regarding Jaguar's plans to evaluate crofelemer for exercise-induced diarrhea (EID) in dogs.

"Elite athletes of all species tend to have more diarrhea than their healthy but more sedentary counterparts, and while the episodes of diarrhea may not be life-threatening, they are nevertheless significant if the goal is peak physical performance. Thus, there is a considerable need in the world of working dogs for products that can reduce the incidence and severity of exercise-induced diarrhea without affecting performance," commented Dr. Michael Davis, DVM, Ph.D., DACVIM, DACVSMR, a veterinary physiologist and board-certified specialist in veterinary internal medicine and veterinary sports medicine at Oklahoma State University, where he conducts research on animal exercise physiology and performance.  MORE


We never take shares as payment for our services. We are paid up to $2000 /mo cash in advance of our initiating our marketing service for most companies.We base any proposed price in conjunction with technical analysis and with client company management fore-knowledge and input.  



Investing in nanocap, microcap, and small cap stocks is highly speculative.  We are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained  has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.